60 yo w/ MSS T4N0 tumor60 yo w/ MSS T4N0 tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?Would you offer an Oncotype DX assay for an otherwise healthy 60-year-old patient with a Grade II, MSS T4N0 (0 out of 20 nodes positive) tumor? If not, what adjuvant systemic therapy would you likely recommend for this patient? 60 yo w/ MSS T3N0 tumor60 yo w/ MSS T3N0 tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?Would you offer an Oncotype DX® assay for an otherwise healthy 60-year-old patient with a Grade II, microsatellite stable (MSS) T3N0 (0 out of 20 nodes positive) tumor? If not, what adjuvant systemic therapy would you likely recommend for this patient? 75 yo w/ MSS T3 (1/20 node pos) tumor75 yo w/ MSS T3 (1/20 node pos) tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?Would you offer an Oncotype DX assay for an otherwise healthy 75-year-old patient with a Grade II, MSS T3 (1 out of 20 nodes positive) tumor? If not, what adjuvant systemic therapy would you likely recommend for this patient? 60 yo w/ MSS T3N0 tumor60 yo w/ MSS T3N0 tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?Would you offer an Oncotype DX assay for an otherwise healthy 60-year-old patient with a Grade II, microsatellite stable (MSS) T3N0 (0 out of 20 nodes positive) tumor? If not, what adjuvant systemic therapy would you likely recommend for this patient? Recommended Obinutuzumab and Rituximab Dosing
Recommended Obinutuzumab and Rituximab DosingThe recommended dose and schedule of obinutuzumab for the approved regimen with chlorambucil in CLL is: The recommended dose and schedule of rituximab for the approved regimen with fludarabine and cyclophosphamide (FC) in CLL is: SecondOpinionMM13/CMETARGET AUDIENCE 60 yo, 2.1-cm node-neg IDC, ER+/HER2-neg adj TC + AI: Systemic Tx if chest wall recurrence 2 y later and NED?60 yo, 2.1-cm node-neg IDC, ER+/HER2-neg adj TC + AI: Systemic Tx if chest wall recurrence 2 y later and NED?60 yo woman, s/p mastectomy for a 2.1-cm IDC, negative nodes. Patient receives TC followed by anastrozole, but 2 years after starting anastrozole a small lesion is removed from the chest wall that proves to be a recurrence. No other disease is detected clinically or on imaging. Both the primary tumor and the recurrence are ER-positive/HER2-negative. What systemic treatment would you recommend? % of pts treated w/ everolimus who require a dose adjustment?% of pts treated w/ everolimus who require a dose adjustment?What proportion of your patients receiving everolimus require dose adjustments for toxicity? Tx PMW ER+/HER2-neg, asymptomatic mets after 3 years adj AI?Tx PMW ER+/HER2-neg, asymptomatic mets after 3 years adj AI?What would you generally recommend for a postmenopausal patient with ER-positive/HER2-negative disease with asymptomatic, higher-volume metastases after receiving adjuvant anastrozole for 3 years? Tx PMW ER+/HER2-neg, asymptomatic mets after 1 year adj AI?Tx PMW ER+/HER2-neg, asymptomatic mets after 1 year adj AI?What would you generally recommend for a postmenopausal patient with ER-positive/HER2-negative disease with asymptomatic, low-volume metastases after receiving adjuvant anastrozole for 1 year? 60 yo, 2.1-cm node-neg IDC, ER+/HER2-neg adj TC + AI: Systemic Tx if chest wall recurrence 2 y later and NED?60 yo, 2.1-cm node-neg IDC, ER+/HER2-neg adj TC + AI: Systemic Tx if chest wall recurrence 2 y later and NED?60 yo woman, s/p mastectomy for a 2.1-cm IDC, negative nodes. Patient receives TC followed by anastrozole, but 2 years after starting anastrozole a small lesion is removed from the chest wall that proves to be a recurrence. No other disease is detected clinically or on imaging. Both the primary tumor and the recurrence are ER-positive/HER2-negative. What systemic treatment would you recommend? % of pts treated w/ everolimus who require a dose adjustment?% of pts treated w/ everolimus who require a dose adjustment?What proportion of your patients receiving everolimus require dose adjustments for toxicity?  |